Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Finasteride effectively lowers specific hormone levels, helping monitor treatment progress.

Estetrol (E4) can help hair grow longer by extending its growth phase.

Cyproterone and finasteride reduced hypersexuality but caused serious side effects.

This study reports a case where a patient with rheumatoid arthritis and alopecia areata saw significant improvement in both conditions after switching to daily upadacitinib treatment, specifically achieving complete hair regrowth within six months.

This study found that cutaneous manifestations in patients undergoing hemodialysis are common and often worsen with longer treatment duration.

This source describes the first successful use of a deslorelin acetate implant to treat alopecia X in a neutered female dog, achieving profuse hair regrowth in 9 months, suggesting an uncomplicated and cost-effective alternative after melatonin failure.

This article highlights the importance of recognizing, preventing, and reporting adverse drug reactions to the FDA's MedWatch program, but does not present new research findings.

This study found that long-term use of 5α-reductase inhibitors is associated with improved overall survival in men with renal cell carcinoma, particularly those with low comorbidity not receiving surgery or systemic therapy, suggesting a potential role for androgen modulation in disease management.

Serenoa repens extract may help hair growth in both men and women.

In this review, spironolactone is highlighted for its emerging use in dermatology, particularly for treating androgen-mediated conditions like acne and hirsutism in susceptible females, though it requires careful monitoring for potential adverse effects.

This study demonstrated that finasteride treatment reduced cardiac dysfunction and hypertrophic remodeling in mice after myocardial infarction, suggesting potential as a therapeutic strategy for heart failure.

In this study, proxalutamide significantly reduced the 30-day hospitalization rate by 91% compared to placebo in men with COVID-19 treated in outpatient settings.

This study reports that ZD1839 (Iressa), an anticancer drug, was associated with acneiform eruptions and hair growth abnormalities due to its inhibition of epidermal growth factor receptor signaling in the skin.

This study found that oral dexamethasone and DPCP were more effective for treating severe alopecia areata compared to oral ritlecitinib and baricitinib, but oral ritlecitinib had better safety outcomes.

This study found that the optimized topical AR antagonist 39, derived from 14-P1, demonstrated potent AR antagonism and comparable efficacy to pyrilutamide in a hair-growth mouse model, with a faster onset and favorable safety profile.

This study found that modeling and simulation effectively informed decision-making and dose selection for ritlecitinib in treating alopecia areata, supporting an accelerated drug development strategy.

This study aimed to characterize the dermatological findings in patients with end-stage renal disease undergoing maintenance hemodialysis and explore their relationship with demographic and clinical features, although specific results are not reported in the abstract.

This article reviews the therapeutic potential of potassium channel openers for various conditions related to metabolic distress but does not report new clinical results; it emphasizes the need for further research.

This systematic review found that treatments for sickle cell disease-related priapism are clinically diverse, with etilefrine, pseudoephedrine/etilefrine-5 inhibitors, and finasteride appearing promising, but further research with robust study designs is needed to establish evidence-based practices.

Captopril may cause hair loss, as shown by a woman's hair regrowing after stopping the medication.

This study found trilostane to be an effective and generally safe treatment for improving symptoms in dogs with pituitary-dependent hyperadrenocorticism.

In this study, JAK inhibitors like baricitinib and ruxolitinib were found to be more effective and caused fewer discontinuations due to adverse events in adults with alopecia areata compared to therapies like dupilumab and apremilast, highlighting the need for more high-quality comparative trials.

This study found that low doses of leuprolide effectively suppressed serum estradiol and LH response, while higher doses were needed to suppress testosterone and reduce hair growth in hirsute women.

This case report describes the first known instance of fixed drug eruption linked to finasteride, confirmed through an oral challenge test that reproduced symptoms at the same skin site.

This study reported improvement of psoriatic onychopachydermoperiostitis symptoms with the use of etanercept.

This study reports the first case of eyelash elongation and thickening in a patient with hypereosinophilic syndrome taking the Janus kinase inhibitor ruxolitinib.